Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7441 to 7455 of 7703 results

  1. Duvelisib for treating relapsed or refractory peripheral T-cell lymphoma [ID5076]

    Discontinued [GID-TA10961]

  2. Etanercept and infliximab for the treatment of psoriatic arthritis (TA104)

    This guidance has been replaced by NICE technology appraisal guidance 199.

  3. Head injury: assessment and early management (CG176)

    This guideline has been updated and replaced by the NICE guideline on head injury: assessment and management (NG232).

  4. Belimumab with rituximab for treating systemic lupus erythematosus [ID3967]

    Discontinued [GID-TA10869]

  5. Palbociclib with trastuzumab and endocrine therapy for maintenance treatment of hormone-receptor positive, HER2-positive metastatic breast cancer [ID6251]

    In development [GID-TA11273] Expected publication date: TBC

  6. Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when high-dose chemotherapy with stem cell transplant is unsuitable [ID3843]

    In development [GID-TA10726] Expected publication date: TBC

  7. Prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia (IPG641)

    This guidance has been updated and replaced by NICE interventional procedures guidance 737.

  8. Ab interno supraciliary microstent insertion with phacoemulsification for primary open-angle glaucoma (IPG605)

    October 2018: The device used in this procedure (CyPass) has been withdrawn by the manufacturer Alcon, because of concerns about its long-term safety. Further details can be found in the Voluntary Field Safety Notice issued by Alcon. Surgeons are advised not to implant this device, to return any unused devices to Alcon and to consider reviewing any patients who have already been implanted with CyPass. Therefore NICE has decided to withdraw its guidance. NICE would consider whether to issue new guidance on ab interno supraciliary microstent insertion with phacoemulsification for primary open-angle glaucoma should evidence using an appropriately CE marked device become available.

  9. Asthma: diagnosis, monitoring and chronic asthma management (NG80)

    This guideline has been updated and replaced by NICE guideline NG245.

  10. Non-invasive skin closure devices for surgical incisions (MT775)

    In development [GID-MT593] Expected publication date: TBC